PLK1 and neoplasm: Rosenblum et al. reported that a single intracerebral injection of CRISPR-LNPs against PLK1 into aggressive orthotopic glioblastoma enabled up to approximately 70% gene editing in vivo, which caused tumor cell apoptosis, inhibited tumor growth by 50%, and improved survival by 30%.